Recent Trading DynamicsAnalyst consensus remains cautious (e.g., “Hold” rating in recent updates, with some price targets lowered post-failure).
marketbeat.com
Some counterbalancing positive signals appeared around the dip period, including institutional filings (e.g., 22NW LP and Mangrove Partners adding shares in mid-March reports).
marketbeat.com
Social/media chatter around the March 13 drop simply noted it as a laggard with no explanatory rumors or new events.
In short, the recent days' selling reflects lingering post-trial overhang, lack of near-term catalysts (next meaningful data is H2 2026), biotech-sector volatility, and typical low-volume trading for a micro-cap name in this position. No fresh negative disclosure occurred. As always, stock movements can be influenced by broader market sentiment, technical factors, or macro conditions—consult real-time quotes, SEC filings, or a financial advisor for personalized context.
Market Data 
Markets 
AI
